<div id="readability-page-1"><div><p>Unfortunately for some shareholders, the <strong>Cresco Labs Inc.</strong> (CSE:CL) share price has dived 37% in the last thirty days, prolonging recent pain.    The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 37% in that time.</p><p> Following the heavy fall in price, Cresco Labs may be sending bullish signals at the moment with its price-to-sales (or &#34;P/S&#34;) ratio of 0.4x, since almost half of all companies in the Pharmaceuticals industry in Canada have P/S ratios greater than 1x and even P/S higher than 3x are not unusual.   Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.   </p> <p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p> <p><span> See our latest analysis for Cresco Labs </span></p><figure><img height="650" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1640" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640"/><figcaption>CNSX:CL Price to Sales Ratio vs Industry November 26th 2025</figcaption></figure><h3> How Has Cresco Labs Performed Recently? </h3><p> While the industry has experienced revenue growth lately, Cresco Labs' revenue has gone into reverse gear, which is not great.   The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better.  If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.    </p><p> Want the full picture on analyst estimates for the company? Then our <strong>free </strong>report on Cresco Labs will help you uncover what's on the horizon.  </p><h2> Is There Any Revenue Growth Forecasted For Cresco Labs?  </h2><p> Cresco Labs' P/S ratio would be typical for a company that's only expected to deliver limited growth, and importantly, perform worse than the industry.  </p><p> In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 9.8%.   The last three years don't look nice either as the company has shrunk revenue by 21% in aggregate.  Therefore, it's fair to say the revenue growth recently has been undesirable for the company.   </p> <p> Turning to the outlook, the next three years should generate growth of 0.4%  each year as estimated by the eight analysts watching the company.  Meanwhile, the rest of the industry is forecast to expand by 5.8% per year, which is noticeably more attractive. </p><p> With this information, we can see why Cresco Labs is trading at a P/S lower than the industry.  It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.  </p> <h2> What We Can Learn From Cresco Labs' P/S? </h2><p> Cresco Labs' P/S has taken a dip along with its share price.      Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company. </p><p> We've established that Cresco Labs maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected.  At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio.  Unless these conditions improve, they will continue to form a barrier for the share price around these levels.     </p><p> It's always necessary to consider the ever-present spectre of investment risk. We've identified<strong> 2 warning signs with Cresco Labs</strong>, and understanding these should be part of your investment process.  </p><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p></div></div>

CRLBF

<p>Cresco Labs Inc. (CSE:CL) shares have slumped 37% in the last 30 days, reflecting poor revenue performance and limited growth prospects. The company's P/S ratio of 0.4x is low compared to the industry, indicating investor concerns. Analysts forecast minimal growth for Cresco Labs, contributing to its reduced stock valuation. Investors are cautious due to weak revenue trends and lower growth expectations compared to the industry.</p>

Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%